Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 21:36:27时区推断·⟳ 抓取 21:39:01·⚡ 决策 07-23 21:41:45 +2m44s·96.4 天前
China SXT Pharmaceuticals宣布900万美元定增并引发股价暴跌
公司拟以每单位2.00美元出售450万单位，募资900万美元，条款相对前收2.02美元接近但包含认股权证，形成显著摊薄。
📄 原文Investing.com↗ 原文
China SXT Pharmaceuticals stock drops on $9M share offering
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea Investing.com -- China SXT Pharmaceuticals I…
不做 China SXT Pharmaceuticals（SXTC.US）
同一具体催化已在近72小时处理过：SXTC.US以每单位2美元定增募资900万美元；本条为重复转述，不再出交易卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 high ↗
关键理由
- 公司拟以每单位2.00美元出售450万单位，募资900万美元，条款相对前收2.02美元接近但包含认股权证，形成显著摊薄。
- 股价已在消息后下跌77.27%至0.4591美元，负面反应已经剧烈兑现。
主要风险
- 同一具体催化已在近72小时处理过，重复推卡会延长同一利空窗口。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,288 字
Oil prices top $100 a barrel after Houthis attack Saudi tankers in Red Sea
Investing.com -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) shares fell 77% Thursday after the company announced a $9 million registered direct offering that will significantly dilute existing shareholders.
The pharmaceutical company entered into a securities purchase agreement with institutional investors to sell 4,500,000 units at $2.00 per unit. Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share.
The warrants will be immediately exercisable upon issuance and will expire one year from the issuance date. The company expects to receive approximately $9 million in gross proceeds before deducting placement agent fees and other offering expenses.
The transaction is expected to close on or about July 24, 2025, subject to customary closing conditions. Univest Securities, LLC is serving as the sole placement agent for the offering.
China SXT Pharmaceuticals, founded in 2005 and headquartered in Taizhou City, Jiangsu Province, focuses on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Investing.com -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) shares fell 77% Thursday after the company announced a $9 million registered direct offering that will significantly dilute existing shareholders.
The pharmaceutical company entered into a securities purchase agreement with institutional investors to sell 4,500,000 units at $2.00 per unit. Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share.
The warrants will be immediately exercisable upon issuance and will expire one year from the issuance date. The company expects to receive approximately $9 million in gross proceeds before deducting placement agent fees and other offering expenses.
The transaction is expected to close on or about July 24, 2025, subject to customary closing conditions. Univest Securities, LLC is serving as the sole placement agent for the offering.
China SXT Pharmaceuticals, founded in 2005 and headquartered in Taizhou City, Jiangsu Province, focuses on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。